Thin
Engineered for high biological fidelity, validated via RP-HPLC and HR-MS, and fully supported for import clearance and technical tech-transfer across Italy.
Italy stands as the undisputed manufacturing powerhouse of the European pharmaceutical industry. With leading industrial clusters concentrated across Lombardy (Milan, Monza-Brianza), Lazio (Rome, Latina), Tuscany (Florence), and Emilia-Romagna, Italy accounts for the highest contract development and manufacturing output in the European Union according to Farmindustria data. Within this thriving manufacturing environment, the demand for specialized, high-barrier gastrointestinal (GI) peptides has expanded rapidly over the past five years.
Gastrointestinal disorders represent one of the most critical public health domains under the Italian National Health Service (Servizio Sanitario Nazionale, SSN). High clinical incidence rates of Irritable Bowel Syndrome with Constipation (IBS-C), Chronic Idiopathic Constipation (CIC), Short Bowel Syndrome (SBS), Ulcerative Colitis, and mucosal radiation injuries have created urgent clinical imperatives. Italian gastroenterological clinics and contract manufacturing organizations (CMOs) require highly stable, chemically defined gastrointestinal peptide APIs—ranging from guanylate cyclase-C (GC-C) agonists like Linaclotide to glucagon-like peptide-2 (GLP-2) analogues like Teduglutide.
Italian pharmaceutical companies and specialized generic dossiers manufacturers (operating under AIC - Autorizzazione all'Immissione in Commercio) face distinct operational bottlenecks when procuring GI peptides domestically or within the traditional European chemical corridor. The structural synthesis of gastrointestinal active substances presents exceptional synthetic hurdles:
Thinheal leverages two decades of synthetic leadership, proprietary solid-phase technologies, and dynamic axial compression chromatography to deliver reproducible batch integrity.
For multicyclic peptides (e.g., Linaclotide), we implement orthogonal cysteine protecting strategies (Acm, Trt, Mob) alongside controlled red-ox buffers to enforce correct regioselective folding, achieving isomeric purity >98.5% before final polishing.
Advanced TFA/scavenger micro-reactor cleavage workstations prevent re-alkylation artifacts and preserve sensitive tryptophan, methionine, and tyrosine residues across large peptide sequences such as Teduglutide.
Equipped with industrial DAC (Dynamic Axial Compression) columns (up to 1000mm diameter) running specialized reverse-phase stationary matrices, ensuring single-run removal of closely migrating deletion and insertion sequences.
| Peptide Name | CAS Number | Sequence Length / Structure | Primary Clinical / R&D Target | Thinheal Purity Standard | Italian Regulatory Status |
|---|---|---|---|---|---|
| Linaclotide | 851199-59-2 | 14-mer, 3 Disulfide Bridges (Cys1-Cys6, Cys2-Cys10, Cys5-Cys13) | IBS-C, Chronic Idiopathic Constipation | ≥98.5% (HPLC) / Any single ≤0.5% | CEP dossier / ASMF ready for AIFA |
| Teduglutide | 287714-30-1 | 33-mer (Gly2-GLP-2 Analogue) | Short Bowel Syndrome (SBS), Intestinal Atrophy | ≥98.0% (HPLC) / Endotoxin <0.05 EU/mg | Full GMP Validation Batches |
| GHK-Cu | 89030-95-5 | Tripeptide (Gly-His-Lys:Cu2+ Complex) | Intestinal Epithelial Repair, Cosmeceuticals | ≥99.0% / Free Copper <0.1% | REACH & CLP Certified for EU Import |
| Dulaglutide | 923950-08-7 | GLP-1 Fc Fusion Protein Mimetic Sequence | Type 2 Diabetes, GI Motility Research | ≥98.0% (SEC-HPLC & RP-HPLC) | R&D and Process Optimization Batches |
| Vasopressin | 50-57-3 | 9-mer Cyclic Peptide (Cys1-Cys6 Disulfide) | Splanchnic Hemorrhage, Vasomotor Stability | ≥99.0% (Ph. Eur. compliant) | Ph. Eur. / USP Grade Monograph |
Removing friction in transatlantic and Sino-European supply chains through dedicated technical documentation and temperature-controlled logistics.
Italian Qualified Persons (QP) and Regulatory Affairs directors require rapid, transparent access to drug substance data. Thinheal provides complete Active Substance Master Files (ASMF / DMF) structured strictly according to the CTD Module 3 formatting rules:
Peptide therapeutic substances are biologically active, hygroscopic, and thermolabile lyophilized powders sensitive to thermal fluctuations during customs clearing at Rome Fiumicino (FCO) or Milan Malpensa (MXP). Our specialized logistical framework guarantees uncompromised material integrity:
Whether you require early-stage feasibility lots or commercial-scale multi-kilogram cGMP batches for gastrointestinal therapeutic programs, our technical management team is on standby to support your program.
Send Inquiry Now - Connect with our EU DeskAnticipating the demands of the European Green Deal and next-generation oral intestinal drug delivery matrices.
Responding to REACH solvent restrictions across Italy and the EU, Thinheal is migrating large-scale solid-phase processes from hazardous DMF and NMP to sustainable alternatives, including cyclopentyl methyl ether (CPME) and 2-methyltetrahydrofuran (2-MeTHF).
Combining chemical fragment condensation with engineered sortases and subtiligases. This hybrid strategy allows the cost-effective assembly of high-molecular-weight peptide therapeutics while abolishing side-chain epimerization.
Collaborating with European CDMO formulation leaders on permeation enhancers (SNAC, sodium caprate) and lipidated peptide analogues designed to withstand gastrointestinal protease degradation for stable once-daily oral administration.
Clear, direct technical answers addressed to Quality Assurance heads, Formulation Chemists, and Global Procurement Officers.
Linaclotide contains three delicate intramolecular disulfide bonds (Cys1-Cys6, Cys2-Cys10, Cys5-Cys13). Improper pairing generates biologically inactive or immunogenic topological isomers. We employ an orthogonal protection approach during solid-phase peptide synthesis (SPPS) using differentiated protecting groups (Trt, Acm, and Mob), followed by step-wise, regioselective oxidative cyclization. Every batch is characterized using high-resolution LC-MS peptide mapping, trypsin digest fragment chromatography, and NMR comparison against reference standard material to confirm 100% correct disulfide connectivity.
Every shipment is released with a comprehensive, batch-specific Certificate of Analysis (CoA) documenting RP-HPLC purity, HR-MS molecular weight, water content (Karl Fischer), residual solvents (GC-HS according to ICH Q3C), residual trifluoroacetic acid (TFA) or acetate content (IC), heavy metals/elemental impurities (ICP-MS compliant with ICH Q3D), bacterial endotoxins (LAL kinetic chromogenic test), and total bioburden. For regulatory filings, we supply full technical dossiers, declarations of origin (BSE/TSE free), nitrosamine risk assessments, and ASMF documentation upon project qualification.
Yes. While standard solid-phase synthetic cleavage yields peptides as trifluoroacetate (TFA) salts, TFA is often restricted or unsuitable for final parenteral or oral formulations in the European Union. Thinheal maintains optimized preparative ion-exchange chromatography systems that replace TFA counter-ions with acetate, hydrochloride, or sodium salts. We routinely achieve residual TFA levels below 0.1% (w/w), accommodating specific formulation solubility and pH targets requested by Italian client development teams.
Thinheal operates an enterprise-grade R&D center and a massive industrial production base in Hangzhou. Our facility integrates automated solid-phase synthesizers ranging from 50L to 1000L reactor volumes, paired with dynamic axial compression HPLC purification columns up to 1000mm in diameter. Our aggregate production capacity for chemically synthesized peptides exceeds multiple metric tons annually, placing us among the select global manufacturers capable of securing uninterrupted multi-kilogram supply campaigns for Italian marketing authorization holders.
Our European logistics desk works directly with accredited Italian customs brokers and freight forwarders specializing in pharmaceutical and chemical transit through Milan Malpensa (MXP) and Rome Fiumicino (FCO). All peptide raw materials, intermediates, and active substances comply with European REACH regulations (Registration, Evaluation, Authorisation and Restriction of Chemicals) and CLP labeling. For active pharmaceutical substances, exemption under Article 2(5)(a) is fully documented in customs declarations.
High-purity therapeutic, metabolic, neuroprotective, and immune-modulatory peptides synthesized under robust quality systems for global and Italian procurement.
Inquire directly with our European project desk for batch documentation, analytical method transfer protocols, or customized pilot synthesis quotes tailored for Italian market supply.